Latest News and Press Releases

Pasithea Tx (Nasdaq: KTTA) activates South Korea trial sites, dosing first NF1 patient in Phase 1/1b NF1 study at Asan Medical Ctr. and Severance Hospital.

Pasithea Tx (Nasdaq: KTTA) advances PAS-004 NF1 trial to Cohort 2 (8mg) after SRC confirms safety; interim data from first two cohorts expected Q1 2026.

Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 8, 2025 in NYC.

Pasithea Tx (Nasdaq: KTTA) to present PAS-004 clinical progress at H.C. Wainwright Global Investment Conference on Sept. 10, 2025 in NYC.

Pasithea completes enrollment and dosing of first NF1 trial cohort; initial safety and efficacy data expected by Q1 2026.

Pasithea adds ETS2 expert Dr. James Lee to its SAB to guide PAS-004 development for IBD and other inflammatory diseases driven by ETS2.

PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients

Pasithea’s PAS-004 shows superior ETS2 inhibition vs. selumetinib, highlighting promise as a new treatment for IBD and other inflammatory diseases.

Pasithea begins PAS-004 Phase 1/1b NF1 trial in Australia, with U.S. and S. Korea sites planned. First dosing set for Q2 2025. 48.5% R&D refund expected.

Pasithea Therapeutics (Nasdaq: KTTA) closes $5M public offering, adds $1.3M via warrant exercises, funding R&D for PAS-004 and other biotech innovations.